-
Yuandong, Koxing... 26 pharmaceutical companies "snatching the beach" section of the board 36 on the road
Time of Update: 2021-03-24
com, China Securities Regulatory Commission, Shanghai Stock Exchange official website, company announcement Medical News, February 25, July 2019, the highly-regarded Sci-tech Innovation Board started to open, detonating the A-share market.
-
See the micro-knowledge-the past of adalimumab and the future of biosimilar drugs
Time of Update: 2021-03-24
In terms of the market performance of adalimumab, according to the statistics of the PDB drug comprehensive database, after the entry of adalimumab into my country’s medical insurance at the end of 2019, despite the impact of the epidemic, the sales volume still increased greatly, and the total sales amount reached 59 million yuan.
-
Deqi Pharmaceutical's Selinexor New Drug Listing Application Receives Priority Review by NMPA
Time of Update: 2021-03-24
On February 24, Deqi Pharmaceuticals announced that the National Medical Products Administration (NMPA) has awarded the world’s first Selective Inhibitor of Nuclear Export ("SINE") ATG-010 (selinexor, XPOVIO®) New drug application (NDA) priority review qualification for the treatment of patients with refractory and relapsed multiple myeloma (rrMM).
-
Junshi Biotech and AstraZeneca Pharmaceuticals signed an exclusive promotion agreement for Tuoyi
Time of Update: 2021-03-24
On February 28th, Junshi Biopharmaceuticals announced that it had signed an "Exclusive Promotion Agreement" with AstraZeneca Pharmaceuticals Co.
In addition, as consideration for the promotion rights granted by Junshi Biotechnology to AstraZeneca, AstraZeneca agreed to pay a down payment to the company after the urothelial cancer indication was approved.
-
2021 The first wave of salary adjustment plans for pharmaceutical companies is coming!
Time of Update: 2021-03-24
However, in addition to the good news of the salary increase, there is also news that Huizhi reduced the county travel subsidy from 2,600 to 1,150 in February this year.
In addition to salary increases, it is reported that this year, pharmaceutical companies have announced salary cuts.
-
Cancer immunotherapy "veteran" IL-2: Can the resurgence of research and development continue to write the PD-1 myth?
Time of Update: 2021-03-24
A variety of engineering IL-2One of the core challenges of converting IL-2 into anti-cancer therapy is cell specificity: Since IL-2 can promote the proliferation of effector T cells and regulatory T cells, is it possible to activate one of them preferentially What about the T cell population?In order to achieve this goal, scientists have been studying the structure of IL-2 receptors for more than a decade.
-
Vaccines | Two more new crown vaccines are on the market to check the current status of domestic COVID-19 vaccine research and development
Time of Update: 2021-03-24
On February 25, the State Food and Drug Administration conditionally approved the new coronavirus inactivated vaccine (Vero cell) of Sinopharm Wuhan Institute of Biological Products and the recombinant new coronavirus vaccine (type 5 adenovirus vector) of Cansino Bio Application for registration of a new crown vaccine.
-
The first domestic Junshi PD-1/TGFβ double antibody clinical application was accepted
Time of Update: 2021-03-24
On February 24, the official website of CDE showed that the clinical application for Junshi Bio-JS201 injection was accepted. JS201 is a PD-1/TGFβ bispecific antibody. At present, no other company i
-
Sanofi and Johnson & Johnson reached a partnership to assist in the production of a new crown pneumonia vaccine
Time of Update: 2021-03-24
Not long before it reached a vaccine cooperation with Johnson & Johnson, Sanofi announced a partnership with Pfizer and BioNTech to assist the two companies in the production of 100 million doses of mRNA vaccines.
-
Behind the sharp correction, we are still optimistic about the chain pharmacy track!
Time of Update: 2021-03-24
Regarding the standard retail industry, taking into account the professionalism and strict supervision of pharmaceutical products (see "The medical e-commerce is here, are chain pharmacies still a good track?"), we It is predicted that the penetration rate of the entire pharmaceutical e-commerce company will not exceed 30% in the next two decades.
-
How does the number and scale of public hospitals develop? The Health and Wellness Commission replied!
Time of Update: 2021-03-24
According to the "Reply", the National Health Commission is studying and revising the national medical and health service system plan, scientifically determining the number, scale and layout of public hospitals and social hospitals, rationally adjusting the bed allocation standards of public hospitals, and supporting some powerful public hospitals On the basis of controlling the size of the single unit, appropriate construction and development of multiple hospitals, and rapid conversion of functions when a major epidemic occurs.
-
The doctors will prepare for them when they return home!
Time of Update: 2021-03-24
On January 25, at the press conference of the two sessions of Hubei Province, it was clearly stated that all township hospitals, community service centers and other grassroots medical and health institutions will set up a large number of empty staff, and it is planned to recruit 10,000 professional health professionals.
-
Aber Maintenance Meile is approved by the FDA for the treatment of children with moderate to severe active ulcerative colitis
Time of Update: 2021-03-24
Compile Ke KeOn February 24, AbbVie announced that the US FDA approved Humira (Adalimumab, trade name Humira) for the treatment of moderate to severe active ulcerative colitis (UC) in children aged 5 years and older.
-
The crime of "drug regulatory malfeasance" is coming today
Time of Update: 2021-03-24
On February 27, the official website of the Supreme People's Procuratorate issued the "Supplementary Provisions on the Implementation of the Criminal Law of the People's Republic of China on Determining Crimes (7)" (hereinafter referred to as the "Supplementary Provisions").
-
Sanofi/Regeneron PD-1 inhibitor approved by FDA for first-line treatment of non-small cell lung cancer
Time of Update: 2021-03-24
Today, Sanofi and Regeneron jointly announced that the US FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) for the first-line treatment of PD-L1 high expression (tumor ratio score ≥50%) Patients with advanced non-small cell lung cancer (NSCLC).
com/news-release/2021/02/22/2179862/0/en/FDA-approves-Libtayo-cemiplimab-rwlc-monotherapy-for-patients-with-first-line-advanced-non-small-cell-lung -cancer-with-PD-L1-expression-of-50.
-
Canley Announces Approval of U.S. Clinical Trial Application for THR-β Agonist ASC41 NASH Indication
Time of Update: 2021-03-24
The approval of the US clinical trial application (IND) is based on a randomized, double-blind, placebo-controlled, single-dose and multi-dose escalation phase I clinical trial with 65 subjects completed in China Efficacy and safety data, as well as the process data of oral tablets developed by Ganlai’s proprietary formulation technology that can be produced commercially.
-
The FDA granted 5808 orphan drug approvals for 38 years after the implementation of the "Orphan Drug Act"
Time of Update: 2021-03-24
In order to change this situation, President Ronald Reagan signed the "Orphan Drug Act" on January 4, 1983, which aims to encourage the development of drugs and treatments for rare diseases and formulate the impact on the pharmaceutical industry.
-
Is presbyopia saved?
Time of Update: 2021-03-24
AGN-190584 is an improved new drug formulation of pilocarpine (a cholinergic muscarinic receptor agonist), which was developed as a once-daily eye drop for the treatment of presbyopia.
If AGN-190584 can be approved, it will be the first eye drop for the treatment of presbyopia, which can provide new treatment options for American patients.
-
National Health Commission: Occupational disease diagnosis should be concluded within 30 days from the receipt of all materials
Time of Update: 2021-03-24
Medical News February 23 The new version of "Occupational Disease Diagnosis and Appraisal Management Measures" is here The diagnostic agency shall make a diagnosis within 30 days from the receipt o
-
The off-season for a batch of medicine sales is here
Time of Update: 2021-03-24
As a manufacturing company, we did not relax the prevention and control of the epidemic during the Spring Festival.
Fight the first battle of post-holiday salesThe Spring Festival has passed and normal sales are about to begin.
